Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00195325

Enrollment

Registered

2005-09-19

Start date

2005-08-31

Completion date

Unknown

Last updated

2007-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms, Tumors

Keywords

Advanced Malignant Solid Tumors

Brief summary

The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Interventions

DRUGTTI-237

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

ECT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented diagnosis of malignant solid tumor with measurable disease * Life expectancy of at least 12 weeks * ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2

Exclusion criteria

* Recent major surgery, radiation therapy or anti-cancer treatment * History of any other prior malignancy within the last 5 years

Design outcomes

Primary

Measure	Time frame
To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.	—

Secondary

Measure	Time frame
Preliminary pharmacokinetics (during cycle 1) and anti-tumor activity of TTI-237 (approximately every 8 weeks).	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026